When is the next dose of WinRho (Rho(D) immune globulin) due for a primigravida at 36+4 weeks gestation who received it at 28 weeks?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

WinRho Postpartum Dosing After 28-Week Antenatal Prophylaxis

For a primigravida at 36+4 weeks who received WinRho at 28 weeks, the next dose is due within 72 hours after delivery if the infant is Rh-positive. 1, 2

Standard Two-Dose Protocol

The American College of Obstetricians and Gynecologists recommends a two-dose protocol that has reduced RhD alloimmunization rates from 1.8% to between 0.1% and 0.2%: 1

  • First dose: 300 μg (1500 IU) at 28 weeks gestation 1, 2
  • Second dose: 300 μg (1500 IU) within 72 hours after delivery if the infant is Rh-positive 1, 2

Critical Timing Considerations

The postpartum dose should be administered preferably within 72 hours of delivery, though it may still provide benefit if given up to 28 days after delivery. 3 Although protection decreases with delayed administration, late administration is still preferable to no administration at all. 4

When the Postpartum Dose May Be Withheld

If delivery occurs within 3 weeks after the 28-week dose (i.e., before 31 weeks gestation), the postpartum dose may be withheld UNLESS there is evidence of fetomaternal hemorrhage exceeding 15 mL of fetal red blood cells. 2

Since this patient is at 36+4 weeks, she is well beyond the 3-week window, so the postpartum dose is definitely required. 2

Dose Modification for Large Fetomaternal Hemorrhage

One standard 300 μg dose provides sufficient antibody coverage for up to 15 mL of fetal red blood cells (approximately 30 mL of whole fetal blood). 2, 3

If a large fetomaternal hemorrhage is suspected at delivery: 2, 3

  • Perform quantitative testing using an approved laboratory technique (e.g., modified Kleihauer-Betke acid elution stain) 2
  • Calculate additional doses needed: divide the red blood cell volume by 15 mL 2
  • If the calculation results in a fraction, round up to the next whole number of doses 2
  • Administer 10 μg additional anti-D for every additional 0.5 mL of fetal red blood cells beyond 15 mL 3

Common Pitfalls to Avoid

Do not assume the 28-week dose provides adequate coverage through delivery and postpartum. The half-life of IgG is 23 to 26 days, and protection must be maintained throughout pregnancy and reinforced after delivery. 2 The antenatal dose at 28 weeks reduces but does not eliminate the need for postpartum prophylaxis. 1

Do not delay postpartum administration while waiting for infant blood typing if there will be any delay beyond 72 hours. While determining the infant's Rh status is important, the 72-hour window is critical for optimal protection. 2, 3

Always confirm the infant's RhD phenotype even if fetal RhD genotyping was performed during pregnancy. 5 The postpartum dose is only necessary if the infant is confirmed Rh-positive. 1, 2

References

Guideline

Management Guidelines for Rh Negative Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevention of Rh alloimmunization.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].

Journal de gynecologie, obstetrique et biologie de la reproduction, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.